All In Biotech

Drug Trial Radar · NCT07265479

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

A Randomized, Double-Blind, Vehicle-Controlled (Period 1) and Open-Label (Period 2) Phase 3 Study to Investigate the Safety and Efficacy of Tapinarof Cream, 1% in Pediatric Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

187

Actual

Start

Dec 29, 2025

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Dec 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 months, up to 23 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • Tapinarof cream, 1%Drug

    Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.

  • Vehicle CreamDrug

    Applied topically once daily to lesions on participant's skin during the Double-Blind period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
  2. Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label PeriodTime frame: Baseline to the end of the Open-Label Period, up to 56 weeks.

Locations

46 sites in 2 countries. Site status is shown where the registry gives one.

  • AllerVie Clinical Research

    Birmingham, Alabama

  • Dermatology Trial Associates

    Bryant, Arkansas

  • Dermatology Research Associates

    Los Angeles, California

  • Integrative Skin Science and Research

    Sacramento, California

  • Allergy and Asthma Medical Group and Research Center

    San Diego, California

  • Clinical Trials Research Institute

    Thousand Oaks, California

  • Clarity Dermatology

    Castle Rock, Colorado

  • Skin Care Research, LLC.

    Boca Raton, Florida

  • APEX Clinical Trials

    Jacksonville, Florida

  • TruDerm Research

    Wellington, Florida

  • Cleaver Medical Group Dermatology, Inc

    Cumming, Georgia

  • Ada West Research

    Meridian, Idaho

  • Endeavor Health Clinical Trials Center

    Skokie, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • The Indiana Clinical Trials Center, PC

    Plainfield, Indiana

  • Equity Medical, LLC

    Bowling Green, Kentucky

  • Lawrence J Green, MD LLC

    Rockville, Maryland

  • Oakland Hills Dermatology

    Auburn Hills, Michigan

  • Minnesota Clinical Study Center

    New Brighton, Minnesota

  • SKY Integrative Medical Center

    Ridgeland, Mississippi

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • Skin Cancer and Dermatology Institute

    Reno, Nevada

  • Forest Hills Dermatology Group

    Kew Gardens, New York

  • Bobby Buka MD, PC

    New York, New York

  • Equity Medical, LLC

    The Bronx, New York

  • The University of North Carolina Dermatology and Skin Cancer Center

    Chapel Hill, North Carolina

  • Dermatologists of Central States, LLC

    Fairborn, Ohio

  • Allergy Asthma and Clinical Research Center

    Oklahoma City, Oklahoma

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • Oregon Health & Science University

    Portland, Oregon

  • Medical University of South Carolina

    Charleston, South Carolina

  • National Allergy and Asthma Research, LLC.

    North Charleston, South Carolina

  • The University of Texas Health Science Center at Houston

    Bellaire, Texas

  • Dermatology Treatment and Research Center

    Dallas, Texas

  • Stryde Research - Epiphany Dermatology

    Southlake, Texas

  • Dermatology Specialists of Spokane

    Spokane, Washington

  • Dermatology Research Institute

    Calgary, Alberta, Canada

  • CARe Clinic (Central Alberta Research Clinic)

    Red Deer, Alberta, Canada

  • Dr. Chih-Ho Hong Medical Inc.

    Surrey, British Columbia, Canada

  • Manitoba Allergy Research Inc.

    Winnipeg, Manitoba, Canada

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.